#United States #New York City #Genetic Therapy #Riaan Research Initiative #Cockayne Syndrome

A Landmark Achievement in Genetic Therapy for Cockayne Syndrome

In a significant advancement for rare disease treatment, the Riaan Research Initiative (RRI) has announced that six-year-old Riaan Singh Digeorge from New York City has become the first patient globally to receive an experimental gene therapy for Cockayne syndrome. This rare genetic disorder, characterized by premature aging and early mortality, has long been without approved treatment options. Riaan's groundbreaking treatment took place on April 21, 2026, at NewYork-Presbyterian Komansky Children's Hospital, led by renowned surgeon Dr. Mark Souweidane.

The Journey to Gene Therapy

This historic milestone represents nearly five years of relentless effort directed by Riaan's parents, Jo Kaur and Richard Digeorge. Following their son’s diagnosis, they established RRI in June 2021 to advocate for research and develop effective treatments for Cockayne syndrome. Fueled by a heartfelt resolve to change the trajectory of their son's life, the couple tirelessly led fundraising initiatives that successfully amassed nearly $4 million.

RRI’s innovative approach deviated from typical drug development pathways. Collaborating with a network of esteemed academic institutions, scientists, and regulatory experts, the initiative not only funded but also guided the transition of the therapy from concept to clinical trials. Key collaborations included preclinical studies at UMass Chan Medical School and toxicology research at Charles River Laboratories leading to full-fledged regulatory submission and approval processes.

A Breakthrough in Treatment

The gene therapy employed is based on adeno-associated viral vector AAV9, designed to deliver a functional copy of the ERCC8/CSA transgene directly into the brain. Encouraging results from preliminary animal studies revealed an impressive 8.5-fold increase in lifespan for mice undergoing the treatment, a finding that spurred the FDA to approve the IND application from UMass Chan.

Jo Kaur, reflecting on her son’s resilience, stated, “We are blown away by Riaan's superhuman spirit. Just a day after surgery, he was laughing and playing balloon volleyball in the Pediatric Intensive Care Unit.” Following two months post-treatment, Riaan continues to showcase extraordinary courage and a zest for life that inspires those around him.

Cockayne syndrome is known to result in severe neurodegeneration, growth impairment, sensory loss, developmental difficulties, and ultimately shortened life expectancy, which in more severe cases could be as low as 5 to 7 years. The rarity of this condition, affecting approximately 1-3 individuals per million, alongside the severity of its symptoms, substantiates a critical need for effective treatment options that remain largely unmet by traditional pharmaceutical approaches.

Future Aspirations

As Riaan copes with his condition, there is hope for expanding the therapy’s reach to other affected children awaiting solutions. Jo Kaur reminisces, “Richie and I never dreamed that our parenting journey would lead us to become drug developers, but love compels us to embrace this challenge.”

The Riaan Research Initiative continues its mission of providing hope to those affected by Cockayne syndrome through advocacy, research funding, and a commitment to expanding treatment opportunities. For the latest updates and insights into their groundbreaking work, visit RRI's blog and social media channels.

By redefining the possibilities for pediatric rare diseases, this historic achievement not only offers hope to families but also paves the way for future innovations in genetic therapies and rare disease management.